9 Biotechnology Stocks to Sell Now

by Portfolio Grader | November 6, 2013 11:15 am

This week, the overall grades of nine Biotechnology stocks are lower, according to the Portfolio Grader[1] database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

Merrimack Pharmaceuticals, Inc.’s (NASDAQ:MACK[2]) rating falls this week to an F (“strong sell”), down from last week’s D (“sell”). Merrimack Pharmaceuticals, Inc. is a biotechnology company, which is focused on the discovery, development and commercialization of drugs for the treatment of immunological and autoimmune diseases with an initial focus on cancer. The firm’s product candidates include MM-398, which is a novel, stable… In Portfolio Grader’s specific subcategories of Earnings Revisions and Cash Flow, MACK also gets F’s. The stock price has dropped 28.9% over the past month, worse than the 1.3% decrease the Nasdaq has seen over the same period of time. As of Nov. 6, 2013, 13.5% of outstanding Merrimack Pharmaceuticals, Inc. shares were held short. For a full analysis of MACK stock, visit Portfolio Grader[3].

Genomic Health, Inc. (NASDAQ:GHDX[4]) is on the decline this week, earning a D (“sell”) after receiving a C (“hold”) last week. Genomic Health is a life science company, which is focused on the development and commercialization of genomic-based clinical diagnostic tests for cancer that allow physicians and patients to make individualized treatment decisions. The stock also gets an F in Earnings Revisions. To get an in-depth look at GHDX, get Portfolio Grader’s complete analysis of GHDX stock[5].

Acorda Therapeutics, Inc. (NASDAQ:ACOR[6]) is having a tough week. The company’s rating falls from a C to a D. Acorda Therapeutics is a commercial stage biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury and other disorders of the central nervous system. The stock gets F’s in Earnings Revisions and Sales Growth. For more information, get Portfolio Grader’s complete analysis of ACOR stock[7].

This week, Amarin Corporation Plc Sponsored ADR (NASDAQ:AMRN[8]) drops from a C to a D rating. Amarin focuses on developing the treatment for cardiovascular disease in the field of lipid science. In Earnings Growth, Earnings Revisions, Equity, and Cash Flow the stock gets F’s. The stock price has fallen 74.4% over the past month. As of Nov. 6, 2013, 15.7% of outstanding Amarin Corporation Plc Sponsored ADR shares were held short. To get an in-depth look at AMRN, get Portfolio Grader’s complete analysis of AMRN stock[9].

Exelixis, Inc. (NASDAQ:EXEL[10]) earns an F this week, moving down from last week’s grade of D. Exelixisis a development-stage biotechnology company dedicated to the discovery and development of small-molecule therapeutics for the treatment of cancer and other serious diseases. The stock gets F’s in Earnings Growth, Earnings Momentum, and Equity. Margin Growth and Sales Growth also get F’s. Share prices fell 6% over the past month. As of Nov. 6, 2013, 22.9% of outstanding Exelixis, Inc. shares were held short. For a full analysis of EXEL stock, visit Portfolio Grader[11].

Trius Therapeutics, Inc.’s (NASDAQ:TSRX[12]) rating weakens this week, dropping to a D versus last week’s C. Trius Therapeutics is a biopharmaceutical company. The stock receives F’s in Earnings Growth, Earnings Momentum, and Equity. Cash Flow and Sales Growth also get F’s. To get an in-depth look at TSRX, get Portfolio Grader’s complete analysis of TSRX stock[13].

Cell Therapeutics, Inc. (NASDAQ:CTIC[14]) experiences a ratings drop this week, going from last week’s C to a D. Cell Therapeutics develops, acquires, and sells new treatments for cancer. The stock gets F’s in Equity and Cash Flow. Investors seem to agree with the downgrade and have pushed down the share price 5.4% over the past month. For more information, get Portfolio Grader’s complete analysis of CTIC stock[15].

Slipping from a C to a D rating, Discovery Laboratories, Inc. (NASDAQ:DSCO[16]) takes a hit this week. Discovery Laboratories is a biotechnology company focused on developing products for the treatment of respiratory disease. The stock gets F’s in Equity and Cash Flow. For a full analysis of DSCO stock, visit Portfolio Grader[17].

This week, Achillion Pharmaceuticals, Inc.’s (NASDAQ:ACHN[18]) rating worsens to a D from the company’s C rating a week ago. Achillion focuses on the discovery, development and commercialization of innovative treatments for infectious diseases. The stock also rates an F in Equity. As of Nov. 6, 2013, 19.5% of outstanding Achillion Pharmaceuticals, Inc. shares were held short. To get an in-depth look at ACHN, get Portfolio Grader’s complete analysis of ACHN stock[19].

Louis Navellier’s proprietary Portfolio Grader[20] stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here[21].

Source URL: https://investorplace.com/2013/11/9-biotechnology-stocks-to-sell-now-mack-ghdx-acor/

---